Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you moved onto 5mg and then saw a higher figure quoted by your provider, you are not imagining it. Mounjaro's UK list price rose sharply from 1 September 2025 when Eli Lilly revised its pricing across all doses, with the highest-dose pens rising from around £122 to around £330. Private providers adjusted their own prices in response, and 5mg — the first therapeutic step up from the starter dose — sits squarely in the affected range. This page explains how UK private pricing now works across the dose ladder, what to expect at the 5mg level, and why the headline number is only part of the story. As a prescription-only medicine, tirzepatide requires a clinical assessment before it can be dispensed; a prescriber, not a price comparison, is the right starting point.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
That moment of hesitation is understandable. You have already done the starter month at 2.5mg, your system has adjusted, and you were expecting to move up smoothly. Then a higher price appears, and you are left wondering whether the increase is real, whether it affects every provider, and whether it is worth pressing on.
The short answer is that the increase is real and industry-wide. Eli Lilly revised Mounjaro's UK list prices from 1 September 2025, and because private pharmacies base their prices partly on the licensed supply chain's wholesale cost, the change filtered through to patients. The detail of why Lilly raised the price and how quickly providers responded is covered separately, but as a broad benchmark: reported private prices since September 2025 typically range between roughly £149 and £375 per monthly pen, depending on the dose and the provider. Those figures are hedged deliberately, they reflect what has been reported across the market, not a guarantee of any single provider's position.
At 5mg specifically, you are no longer in starter territory. If you are curious how the Mounjaro price increase at the 2.5mg starting dose compares to what you are now seeing quoted for higher doses, that page breaks down the distinction in detail. That distinction matters when you are thinking about value, not just cost. Pausing treatment because of a price shock carries its own consequences, and our prescribers hear this concern regularly.
A price for a Mounjaro pen and a price for Mounjaro treatment are not always the same thing. This is worth unpacking carefully, because the gap can be substantial.
Some providers quote the cost of the pen alone. That means a consultation fee lands separately. So does the prescription charge. Delivery (often express, because temperature-controlled medicine needs it) is sometimes added at checkout. And aftercare, the clinical check before your next dose increase or repeat, may be a separate appointment. When you add those components together, the apparent saving over a more inclusive price can shrink or disappear entirely.
There is also the question of clinical re-review. Every time you move up a dose on the licensed titration schedule, a prescriber should be assessing whether the increase is appropriate for you. If that step is automated rather than human, or skipped, the lower price reflects a lower standard of care rather than a genuine efficiency. For background on how the wider Mounjaro price increase has played out across providers, and what to look for when comparing quotes, that page covers the landscape in more detail. To understand the full picture of how the Mounjaro cost increase affects what patients actually pay once all components are included, that page sets out the detail clearly.
The NICE appraisal of tirzepatide (TA1026) and NHS England's guidance both assume that treatment happens within a framework of clinical review and lifestyle support. Private treatment should reflect the same standard, even if it sits outside the NHS system.
We are not the cheapest option for 5mg tirzepatide. We say that deliberately, because we think it is the honest way to have this conversation.
What our price includes: the consultation, the prescription, the medicine, next-working-day tracked DPD delivery in plain packaging, and priority aftercare seven days a week. There is no subscription. Each repeat order is reviewed by a named prescriber before it goes out. If you order before 12pm on a working day and your consultation is clinically approved, your pen is dispatched that same day and arrives the following working day, it goes straight into the fridge door alongside the rest of your evening routine, ready for your next scheduled dose.
You can verify that we are a GPhC-registered pharmacy by checking our entry on the GPhC register (registration number 9012878). That is not a formality; it is the baseline check anyone should run before sending payment to an online pharmacy dispensing a prescription-only medicine. More detail on what to look for (and what to avoid) is on our Mounjaro price context page.
If you want to understand what the full cost picture looks like across the dose schedule, our Mounjaro pricing page walks through how private treatment is structured from 2.5mg upward.
Tirzepatide is a Prescription-Only Medicine. That designation exists because these medicines require proper clinical assessment, they interact with other conditions, other medicines, and individual health histories in ways that matter. The MHRA has been explicit that GLP-1 medicines are not assessed for quick or cosmetic weight loss, and the MHRA's Yellow Card scheme continues to receive reports linked to products obtained through unverified routes.
A small saving is not the measure that keeps you safe when the medicine involved requires a licensed supply chain, cold-chain logistics, and a prescriber who can spot a contraindication. Fake pens have been seized in the UK containing entirely wrong substances. The right test when choosing a provider is not the lowest quoted figure, it is whether the pharmacy is GPhC-registered, whether a real prescriber reviews your case, and whether the medicine is sourced through a UK-licensed channel.
If you are continuing from the starter dose and wondering whether moving to 5mg is still worth it given the price increase, that is a clinical question as much as a financial one. Our prescribers are the right people to work through it with you. You can explore our treatment options or read about weight management more broadly before you decide. When you are ready, start a free consultation and a prescriber will review your situation the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.